ZIVO Bioscience Inc. (ZIVOW)
ZIVO Bioscience Statistics
Share Statistics
ZIVO Bioscience has 39.98M shares outstanding. The number of shares has increased by 42.13% in one year.
| Shares Outstanding | 39.98M |
| Shares Change (YoY) | 42.13% |
| Shares Change (QoQ) | 0.6% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.3M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is null. ZIVO Bioscience's PEG ratio is undefined.
| PE Ratio | undefined |
| Forward PE | n/a |
| PS Ratio | 73.35 |
| Forward PS | null |
| PB Ratio | -0.92 |
| P/FCF Ratio | undefined |
| PEG Ratio | undefined |
Enterprise Valuation
ZIVO Bioscience has an Enterprise Value (EV) of 2.16M.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.15, with a Debt / Equity ratio of undefined.
| Current Ratio | 0.15 |
| Quick Ratio | 0.15 |
| Debt / Equity | undefined |
| Debt / EBITDA | - |
| Debt / FCF | - |
| Interest Coverage | undefined |
Financial Efficiency
Return on Equity is 3.53% and Return on Invested Capital is 390.59%.
| Return on Equity | 3.53% |
| Return on Assets | -13.99% |
| Return on Invested Capital | 390.59% |
| Revenue Per Employee | $3.46K |
| Profits Per Employee | $-972.15K |
| Employee Count | 8 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.26, so ZIVO Bioscience's price volatility has been higher than the market average.
| Beta | 0.26 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 1.28 |
| 200-Day Moving Average | 0.63 |
| Relative Strength Index (RSI) | 56.27 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, ZIVO Bioscience had revenue of 27.65K and earned -7.78M in profits. Earnings per share was -4.6.
| Revenue | 27.65K |
| Gross Profit | 11.61K |
| Operating Income | -7.26M |
| Net Income | -7.78M |
| EBITDA | -7.26M |
| EBIT | -7.26M |
| Earnings Per Share (EPS) | -4.6 |
Balance Sheet
The company has 274.38K in cash and 346.34K in debt, giving a net cash position of -71.96K.
| Cash & Cash Equivalents | 274.38K |
| Total Debt | 346.34K |
| Net Cash | -71.96K |
| Retained Earnings | -123.58M |
| Total Assets | 495.59K |
| Working Capital | -2.14M |
Cash Flow
In the last 12 months, operating cash flow was -5.8M and capital expenditures 0, giving a free cash flow of -5.8M.
| Operating Cash Flow | -5.8M |
| Capital Expenditures | 0 |
| Free Cash Flow | -5.8M |
| FCF Per Share | -3.43 |
Margins
Gross margin is 41.99%, with operating and profit margins of -26267.67% and -28127.25%.
| Gross Margin | 41.99% |
| Operating Margin | -26267.67% |
| Pretax Margin | -28127.25% |
| Profit Margin | -28127.25% |
| EBITDA Margin | -26267.67% |
| EBIT Margin | -26267.67% |
| FCF Margin | -20976.1% |
Dividends & Yields
ZIVOW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for ZIVOW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -468.9 |
| Piotroski F-Score | 2 |